Vitro BioPharma
Vitro BioPharma develops Wharton's jelly-derived allogeneic mesenchymal stem cell therapies (AlloRx) for autoimmune and inflammatory disorders, while selling research-grade MSCs, cancer-associated fibroblasts, MSC-Gro culture media, cosmeceuticals, and secretome products to academic, biotech, pharmaceutical, and international clinical customers.
- Company typePublic
- Founded1986
- HeadquartersDenver, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Vitro BioPharma does
Vitro BioPharma is a Denver, Colorado-based biologics company developing Wharton's jelly-derived mesenchymal stem cell therapies for autoimmune and inflammatory disorders. Its lead investigational candidate, AlloRx Stem Cell therapy, is an off-the-shelf, cryopreserved allogeneic cell product manufactured under cGMP using proprietary MSC-Gro specialty culture media developed over 20+ years of internal R&D. The company holds FDA authorization to conduct Phase 1/2a clinical trials for Pitt-Hopkins Syndrome and Long COVID, with planned IND applications for Lupus/SLE and Multiple Sclerosis; enrollment is expected to commence in 2026 contingent on funding. Manufacturing occurs at an ISO 9001:2015 and ISO 13485:2016 certified, FDA-registered cGMP facility in Golden, Colorado.
The company operates a diversified revenue model spanning research products, international clinical supply, consumer health, and (future) therapeutic commercialization. It sells research-grade human MSCs (umbilical cord, placenta, bone marrow, adipose-derived), cancer-associated fibroblasts from 13 cancer indications, human fibroblasts, and MSC-Gro media variants through a Shopify-based e-commerce storefront to universities, biotech, and pharmaceutical buyers, with unit prices ranging from approximately $286 to $2,642. AlloRx Stem Cells are supplied to foreign third-party clinics running patient-sponsored studies across at least 11 indications. The wholly-owned InfiniVive MD subsidiary distributes stem cell-based cosmeceuticals, while the Stemulife sub-brand (acquired via Fitore) sells nutraceutical stem-cell-activation supplements. The June 2024 launch of AlloEx, a secretome/exosome product for dermatological applications, marks entry into the regenerative aesthetics vertical.
The leadership team combines scientific founder continuity (Dr. Jim Musick, CSO and co-founder) with capital-markets and regulatory expertise brought in by CEO Chris Furman (formerly of Janus Henderson, ArrowMark, Virtus), CFO Thomas Ohrt (appointed January 2024), and Chair/CRO Dr. Caroline Mosessian. Co-founded in 1986, Vitro BioPharma is a small organization (1-10 employees) with a documented safety profile of 381+ subjects treated internationally with no serious adverse events related to AlloRx Stem Cells.
Vitro BioPharma firmographics
Firmographics- Name
- Vitro BioPharma
- Legal name
- Vitro Biopharma, Inc.
- Website
- https://vitrobiopharma.com
- Company type
- Public
- Founded year
- 1986
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Vitro BioPharma develops Wharton's jelly-derived allogeneic mesenchymal stem cell therapies (AlloRx) for autoimmune and inflammatory disorders, while selling research-grade MSCs, cancer-associated fibroblasts, MSC-Gro culture media, cosmeceuticals, and secretome products to academic, biotech, pharmaceutical, and international clinical customers.
- Ownership category
- akta.pro rank
Vitro BioPharma industry classification
Industry- Product category
- Regenerative Medicine / Cell Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)
- akta.pro secondary industries
- Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB), Stem Cell–Based Regenerative Therapies (HLAAAGAA), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where Vitro BioPharma is headquartered
LocationHeadquarters
- HQ city
- Denver
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Vitro BioPharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Stem Cell Research Products: Sale of stem cell products including Human Umbilical Cord Derived MSCs, Human Placenta Derived MSCs, Human Bone Marrow Derived MSCs, Human Adipose Derived MSCs, and Cancer-Associated Fibroblasts (CAFs) to research institutions, biotechnology firms, pharmaceutical companies, and universities.
- Cell Culture Media Products: Sale of MSC-Gro brand cell culture media products including VitroPlus III Low-Serum Complete MSC Medium and specialized CAF maintenance media.
- InfiniVive MD Cosmeceuticals: Revenue from sale of stem cell products and cosmeceuticals via InfiniVive MD subsidiary to consumers and clinics.
- Foreign Clinical Study Supply: Supply of AlloRx Stem Cells to foreign third-party clinics conducting patient-sponsored clinical studies for various indications.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Human Umbilical Cord Derived MSCs - 500,000 cells |
| Unit Pricing | Pay-as-you-go | Human Bone Marrow Derived MSCs - 500,000 cells |
| Unit Pricing | Pay-as-you-go | Human Adipose Derived MSCs - 500,000 cells |
| Unit Pricing | Pay-as-you-go | Cancer-Associated Fibroblasts (CAFs) - 1,000,000 cells |
| Unit Pricing | Pay-as-you-go | MSC-Gro Cell Culture Media - 500mL |
| Unit Pricing | Pay-as-you-go | Human Fibroblasts - 1,000,000 cells |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Vitro BioPharma product offering
Product offeringCore offering
Vitro BioPharma develops and commercializes Wharton's jelly-derived mesenchymal stem cell (MSC) therapies under the AlloRx Stem Cell brand for autoimmune and inflammatory disorders. The company sells research-grade MSC lines, cancer-associated fibroblasts (CAFs), and proprietary MSC-Gro specialty culture media to research institutions, biotech, and pharmaceutical firms, and operates an InfiniVive MD subsidiary for stem cell cosmeceuticals.
Product overview
Vitro Biopharma is a biologics company developing Wharton's jelly-derived cell therapies. The core product is AlloRx Stem Cell therapy, an off-the-shelf cell-based treatment derived from umbilical cord-derived MSCs. The company manufactures research-grade products including various MSC types (umbilical cord, placenta, bone marrow, adipose-derived), cancer-associated fibroblasts from multiple cancer types, and human fibroblasts. Supporting products include MSC-Gro culture media in multiple formulations (low-serum, serum-free, xeno-free, CAF-specific). Through its InfiniVive MD subsidiary, the company sells stem cell products and cosmeceuticals. The Stemulife nutraceutical brand (Brain Grow Activator, Brain Grow Stimulator, Brain Grow Energizer) supports stem cell activation. Recent expansion includes AlloEx secretome products for regenerative aesthetics.
Differentiator
Problem solved
Functional benefit
Brands
- AlloRx: AlloRx Stem Cell therapy and AlloRx Stem Cells - cell-based therapy product derived from umbilical cord-derived mesenchymal stem cells
- MSC-Gro
- AlloEx
- Stemulife
Products and services
- AlloRx Stem Cell therapy
Quantifiable outcome
- Over 381 subjects treated in clinical trials with no serious adverse events related to AlloRx Stem Cells
- +1 more outcomes
Companies that use Vitro BioPharma
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
Vitro BioPharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Vitro BioPharma partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- University of Illinois College of Medicine at PeoriacoreCollaborative research relationship for pre-clinical studies of stem cell therapy for stroke. Researchers conducted animal studies showing protective effects of human umbilical cord blood-derived MSCs in rat models of ischemic stroke, demonstrating reversal of apoptosis and prevention of DNA damage.
- International Clinics (Foreign Third-Party)minorSupply of AlloRx Stem Cells to foreign third-party clinics conducting patient-sponsored clinical studies for various indications including ARDS due to COVID-19, Long COVID, MS, ALS, Lupus, MSA, Alzheimer's disease, CKD, COPD, diabetes and age-related conditions.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Vitro BioPharma competitors and assessment
Company assessmentDirect peers
- Mesoblast: Commercial-stage allogeneic cell therapy company developing mesenchymal lineage cell therapies for inflammatory and autoimmune diseases (e.g., remestemcel-L). Direct competitor to Vitro's AlloRx platform in the MSC-based immunology space.
- Pluristem Therapeutics: Developer of placenta-derived, off-the-shelf cell therapy products (PLX cells) for inflammatory and ischemic conditions. Comparable to Vitro in perinatal-tissue MSC source and allogeneic off-the-shelf positioning.
- Athersys / Healios: Developer of MultiStem, an off-the-shelf allogeneic cell therapy being evaluated in inflammatory and immune-mediated conditions. Closely comparable to Vitro's AlloRx in modality, manufacturing approach, and indication focus.
- Lineage Cell Therapeutics: Clinical-stage cell therapy company developing allogeneic cell transplant programs in immunology and CNS. Comparable in allogeneic off-the-shelf modality and therapeutic focus areas adjacent to Vitro's pipeline.
- BrainStorm Cell Therapeutics: Clinical-stage developer of autologous MSC-based therapies (NurOwn) for neurodegenerative and autoimmune indications. Comparable in cell-therapy modality and indication adjacency to Vitro's pipeline.
- ATCC: Global biological resource center supplying authenticated cell lines, including MSCs and cancer-associated fibroblasts, to research customers. Directly comparable to Vitro's research MSC and CAF product portfolio for academic/biotech buyers.
- Stemcell Technologies: Major supplier of specialty cell culture media, primary cells, and reagents for stem cell research. Directly comparable to Vitro's MSC-Gro media franchise and research MSC product line serving academic and pharma researchers.
Broad incumbents
- Lonza Group: Global CDMO and cell-and-gene-therapy manufacturing leader with extensive cGMP capacity. Comparable in the underlying cGMP cell-therapy manufacturing capability Vitro operates in its Golden, CO facility, and a potential partner/competitor.
- Organogenesis Holdings: Commercial regenerative medicine company selling cell-based and tissue products for wound care and surgical applications. Overlaps with Vitro's InfiniVive MD/AlloEx cosmeceutical and regenerative aesthetics ambitions at the broader industry level.
Emerging players
- Fate Therapeutics: Developer of iPSC-derived off-the-shelf NK and T-cell therapies. Adjacent in the broader allogeneic off-the-shelf cell therapy space with overlapping autoimmune/inflammatory ambitions but distinct cell source.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Vitro BioPharma social profiles
Digital presenceVitro BioPharma compliance and trust
Trust signalCompliance4 records
Vitro BioPharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vitro BioPharma leadership team
Management profileNumber of profiles
Profiles6 records
Vitro BioPharma subsidiaries and ownership
Company hierarchySubsidiaries1 record
Vitro BioPharma funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vitro BioPharma M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vitro BioPharma
What does Vitro BioPharma do?
Vitro BioPharma develops and commercializes Wharton's jelly-derived mesenchymal stem cell (MSC) therapies under the AlloRx Stem Cell brand for autoimmune and inflammatory disorders. The company sells research-grade MSC lines, cancer-associated fibroblasts (CAFs), and proprietary MSC-Gro specialty culture media to research institutions, biotech, and pharmaceutical firms, and operates an InfiniVive MD subsidiary for stem cell cosmeceuticals.
Is Vitro BioPharma a public or private company?
Vitro BioPharma is a public company. It is classified as public and is currently operating.
When was Vitro BioPharma founded?
Vitro BioPharma was founded in 1986. It employs 1 to 10 people.
Where is Vitro BioPharma based?
Vitro BioPharma is headquartered in Denver, United States, in the North America region.
How does Vitro BioPharma make money?
Four revenue lines are on record. Stem Cell Research Products are the primary driver. The others are cell Culture Media Products, infiniVive MD Cosmeceuticals and foreign Clinical Study Supply.
Who are Vitro BioPharma's main competitors?
Direct peers on record are Mesoblast, Pluristem Therapeutics, Athersys / Healios, Lineage Cell Therapeutics, BrainStorm Cell Therapeutics, ATCC and Stemcell Technologies. Broad incumbents are Lonza Group and Organogenesis Holdings. Fate Therapeutics is listed as an emerging player.
Does Vitro BioPharma have an API?
No public API is recorded for Vitro BioPharma.
What industry is Vitro BioPharma in?
Vitro BioPharma's product category is Regenerative Medicine / Cell Therapy. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf). Its NAICS code is 325414 and its SIC code is 2836.